Universitätsklinikum Ulm

The phenotype of adverse drug effects: Do emergency visits due to adverse drug reactions look different in older people? Results from the ADRED study (2020) Just KS, Dormann H, Schurig M, Böhme M, Steffens M, Plank-Kiegele B, Ettrich K, et al. Journal article Update Breast Cancer 2020 Part 3 - Early Breast Cancer (2020) Huober J, Schneeweiss A, Hartkopf AD, Müller V, Lux MP, Janni W, Ettl J, et al. Journal article, Review article Treatment landscape and prognosis after treatment with trastuzumab emtansine (2020) Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, et al. Journal article Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer (2020) Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, et al. Journal article, Review article Older age onset of systemic sclerosis - accelerated disease progression in all disease subsets (2020) Moinzadeh P, Kuhr K, Siegert E, Mueller-Ladner U, Riemekasten G, Günther C, Kötter I, et al. Journal article A novel mouse model to study fracture healing of the proximal femur (2020) Haffner-Luntzer M, Weber B, Lam C, Fischer V, Lackner I, Ignatius A, Kalbitz M, et al. Journal article Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020) Laakmann E, Witzel I, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mobus V, et al. Conference contribution Does Induction of Labor for Preterm Premature Rupture of Membranes at 34 Weeks of Gestation Increase the Risk for Cesarean Section Erhöht die Geburtseinleitung wegen eines frühen vorzeitigen Blasensprungs ab 34+0 SSW das Risiko für einen Kaiserschnitt (2020) Puhl A, Weiss C, Schneid A, Zahn E, Kraft K, Pretscher J, Faschingbauer F, et al. Journal article Use of a molecular Registry (PRAEGNANT) for Patient-Selection and Biomarker-Analysis for the SHERBOC Study (2020) Hübner H, Kurbacher C, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, et al. Conference contribution Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab (2020) Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, et al. Journal article